Optimal Management of Favorable Risk Clear Cell RCC Combination Therapy

Optimal Management of Favorable Risk Clear Cell RCC Combination Therapy

User Photo
kidneycancer

10 months
39 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
André P. Fay, MD, PhD Professor, PUCRS School of Medicine Chief, Medical Oncology Department - Oncoclínicas/HSL-PUCRS Visiting Scientist at Dana-Farber Cancer Institute/ Harvard Medical School discusses
Optimal Management of Favorable Risk Clear Cell RCC Combination Therapy at the 18th International Kidney Cancer Symposium 2019, Miami, FL.



Up Next Autoplay